Latest News

Attune Medical Major Milestones: Including ensoETM in Cardiac Ablation Procedures Published Study and $4 Mil Convertible Note Closing

Dr. Mark Gallagher (St. George’s University Hospital, London UK) evaluated the use of the ensoETM in cardiac ablation procedures to ascertain whether using the esophageal space for temperature management could have the potential to decrease collateral thermal injury related to radio-frequency (RF) ablation for the treatment of atrial fibrillation.

Signia Introduces World’s First ‘Face Mask Mode’ for Hearing Devices: Improves Audibility for Those Communicating with Someone Wearing a Face Covering & No More Lip Reading

“The hearing challenges presented by face masks became obvious pretty quickly into the pandemic, so Signia developed the first-of-its-kind Face Mask Mode to help those with hearing loss better communicate in this new reality,” said Tish Ramirez, Au.D. of Signia. “When this setting is activated, the hearing aids optimally capture the sound of the speech signals, enabling the words to sound clearer and reducing any background noise to help the wearer understand what is being said.” 

Modulim Announces CE Mark of Clarifi Imaging System for Microvascular Assessment

Modulim can now expand its marketing and distribution throughout Europe and apply for registration in other international markets that recognize the CE Mark.

Genius AI Detection Receives FDA Clearance

Hologic notes the new technology which the company has now made commercially available represents a pivotal milestone in the early detection of breast cancer, as studies showed Genius AI Detection software aids in the identification and early detection of breast cancer when used with the Genius 3D Mammography exam.

Radcliffe Group Ltd Appoints New Chief Technical Officer and Scientific Director

August 27, 2020

Radcliffe Group Ltd. has announced the appointment of a new chief technical officer and scientific director.

Wells Powell, Radcliffe GroupRadcliffe Group reports: Wells Powell (top right) has been working in technology for over 25 years and spent most of his career working as part of the IT Management team at French Bank BNP Paribas. Wells has held senior roles across development and production, managing large teams across multiple territories. During a career of over 21 years at BNPP, Wells was responsible for leading several strategic projects across electronic trading, eCommerce and digital transformation. His role as CTO at RG will be pivotal to the strategic implementation of the technological infrastructure associated with their data analytics and media production development plans.

Wells Powell comments: “After working with RG on their continued digital transformation as a consultant for 18 months, I am excited to be joining RG on a permanent basis and being involved more formally in the digital strategy of the company. RG delivers high-quality digital content and continually push boundaries to bring new and innovative products for the advancement of educating cardiovascular physicians to market. I look forward to being involved in their continuous growth with this ambitious team.”

Sean Delaney (bottom-right) joins RG with a wealth of Medical Education and Communications experience, most recently from his Board position at OmniaMed Communications where he managed the editorial team, led the scientific strategy, and approved all medical content. Prior to that role, Sean was Principal Medical Writer at PCM Scientific. His most notable work included the execution of an award-winning CME-accredited outreach program in heart failure (Winner, Communique Awards 2017). Sean’s appointment further emphasizes RG’s commitment to the production of world-class medical content. His experience will see him working closely with the existing Chief Scientific Officer, Dr. Greg Guillory, to oversee the content development process from inception ensuring highest quality standards are adhered to and learning objectives obtained.

Sean Delaney comments: “Having watched from the sideline for several years, I’ve been consistently impressed by the quality and innovation of RG’s digitally-focused content. I’m excited to be joining the team and also bringing some of my own insight and experience from the world of cardiology, to continue the success of RG’s medical education.”

Liam O’Neill, COO, RG comments: “Both David, myself and the board of directors are delighted that Wells and Sean have chosen Radcliffe Group for the next chapter of their careers. Both have considerable reputations in their respective fields of specialism and it is a real coup to bring them into the leadership group of our growing company. Their expertise and enthusiasm will be crucial to enabling the business to maximize its potential in the coming months and years. We are really excited to welcome them to the Radcliffe team and witness the impact they will inevitably make.”

Radcliffe Group Ltd is the holding company of operating businesses Radcliffe Medical Media and Radcliffe Medical Education. Radcliffe Medical Media comprises the Radcliffe Cardiology and Radcliffe Vascular content platforms, publishing six industry-leading open access, peer-reviewed journals: Arrhythmia & Electrophysiology Review (AER), Cardiac Failure Review (CFR)European Cardiology Review (ECR)Interventional Cardiology Review (ICR)US Cardiology Review (USC) and Vascular & Endovascular Review (VER). Radcliffe Medical Education delivers trusted independent CME accredited and non-accredited educational programs in multiple media formats for the benefit of cardiovascular physicians globally, via its learning management web platform, Radcliffe Education and during in-person medical congresses.

Latest Posts

Fusion Antibodies and Queen’s University Belfast Awarded a £453,000 Grant from Invest Northern Ireland

The two organisations will use the funds to accelerate the discovery of novel therapeutic and diagnostic antibodies with validated anti-infective properties against COVID-19. Building on strong scientific knowhow, a new antibody development platform will be created that will help realise the vision of producing a breakthrough therapeutic that directly targets SARS-CoV-2.

Attune Medical Major Milestones: Including ensoETM in Cardiac Ablation Procedures Published Study and $4 Mil Convertible Note Closing

Dr. Mark Gallagher (St. George’s University Hospital, London UK) evaluated the use of the ensoETM in cardiac ablation procedures to ascertain whether using the esophageal space for temperature management could have the potential to decrease collateral thermal injury related to radio-frequency (RF) ablation for the treatment of atrial fibrillation.

Signia Introduces World’s First ‘Face Mask Mode’ for Hearing Devices: Improves Audibility for Those Communicating with Someone Wearing a Face Covering & No More Lip Reading

“The hearing challenges presented by face masks became obvious pretty quickly into the pandemic, so Signia developed the first-of-its-kind Face Mask Mode to help those with hearing loss better communicate in this new reality,” said Tish Ramirez, Au.D. of Signia. “When this setting is activated, the hearing aids optimally capture the sound of the speech signals, enabling the words to sound clearer and reducing any background noise to help the wearer understand what is being said.” 

Kayentis, a global provider of digital data capture systems for clinical trials, today announces it has raised €7M (approx. $8.3M) in growth capital.

Kayentis is active in the global electronic Clinical Outcome Assessment (eCOA) market, which is expected to reach $2.6 billion by 2027. Market growth in eCOA – a method of capturing outcomes data electronically in clinical trials – is driven by the clinical trials industry.

Don't Miss

New England Biolabs® Introduces NEBNext® Custom RNA Depletion Design Tool and RNA Depletion Core Reagent Set for Customizable RNA Depletion

This technology has been superb for eliminating the ribosomal RNA for a range of custom projects, including tracking novel viruses in mosquitoes, longitudinal profiling for astronauts, and host-pathogen interactions in COVID samples.

INTERCEPT Blood System for Cryoprecipitation Receives FDA Approval States Cerus Corporation

"FDA approval of the INTERCEPT Blood System for Cryoprecipitation is an important step forward in our mission to establish pathogen reduction as the standard of care for transfused blood components globally," said William ‘Obi’ Greenman, Cerus’ president and chief executive officer.

Research Paper Showing ProtoKinetix AAGP® Enhanced Stem Cell Derived Retina Precursor Cells Restoration of Vision

ProtoKinetix notes the research paper has been submitted to a prestigious journal specializing in tissue regeneration for peer review and editing.

OrganaBio to Expand Its cGMP Cell and Gene Therapy Manufacturing Facility: 19,000 Sq. Ft. Slated to Commence Operations In Q3 2021

OrganBio, a Miami-based cGMP facility, will include process development space, ISO 7 cleanrooms, state-of-the-art scientific equipment, analytics and QC laboratories, and a suite of support services to enable OrganaBio and its partners to rapidly and economically self-manufacture clinical materials. 

Stoke Therapeutics Announces Proposed Public Offering

November 18, 2020 Stoke Therapeutics, Inc., a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein...